Skip to main content
S

Stackstaging

The startup is commercializing a vascular device technology platform designed for intravascular treatment of critical limb ischemia, specifically targeting complex lesions in the peripheral vasculature. This technology addresses the limitations of current endovascular surgical methods, enhancing treatment options for patients with severe vascular conditions.

Galway, Ireland
Updated 2 months ago

Funding

Funding not disclosed

Funding rounds are not available yet.

Founders

Founder details are not available yet.

Product

Problem

Patients with critical limb ischemia (CLI) often suffer from severe arterial blockages, known as chronic total occlusions (CTOs), in their lower extremities. Current endovascular surgical methods struggle to effectively treat these complex lesions, especially when calcified, leading to high rates of failed procedures, amputations, and mortality. The inability to cross these blockages with conventional guidewires limits treatment options and contributes to poor patient outcomes.

Solution

Versono is developing an intravascular ultrasonic technology platform designed to transform the endovascular treatment of complex, chronic, and acute vascular occlusions associated with CLI. The system aims to enable physicians to efficiently cross these lesions, prepare a working lumen, and support the delivery of subsequent intravascular therapies. By utilizing a novel ultrasonic approach, the technology seeks to overcome the challenges posed by calcified segments and heterogeneous occlusions, ultimately improving revascularization rates and limb preservation.

Target Audience

The primary target audience includes vascular surgeons, interventional radiologists, and other clinicians specializing in the treatment of peripheral arterial disease (PAD) and critical limb ischemia (CLI).

Features

  • Intravascular ultrasonic system for crossing complex, chronic, and acute vascular occlusions
  • Designed to prepare a working lumen to facilitate treatment
  • Supports the delivery of follow-on intravascular therapies
  • Addresses challenges posed by calcified segments and heterogeneous occlusions
  • Aims to improve revascularization rates and limb preservation in CLI patients
This profile is AI-generated and may contain inaccuracies.